251 related articles for article (PubMed ID: 30830867)
41. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
[TBL] [Abstract][Full Text] [Related]
42. High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel.
Luo Y; Wang X; Wang H; Xu Y; Wen Q; Fan S; Zhao R; Jiang S; Yang J; Liu Y; Li X; Xiong W; Ma J; Peng S; Zeng Z; Li X; Phillips JB; Li G; Tan M; Zhou M
PLoS One; 2015; 10(9):e0138955. PubMed ID: 26406239
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7.
Gong J; Cui Z; Li L; Ma Q; Wang Q; Gao Y; Sun H
Tumour Biol; 2015 Sep; 36(10):7831-40. PubMed ID: 25944166
[TBL] [Abstract][Full Text] [Related]
44. FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma.
Li MR; Zhu CC; Ling TL; Zhang YQ; Xu J; Zhao EH; Zhao G
BMC Gastroenterol; 2017 May; 17(1):60. PubMed ID: 28464881
[TBL] [Abstract][Full Text] [Related]
45. miR‑27a promotes human breast cancer cell migration by inducing EMT in a FBXW7‑dependent manner.
Jiang G; Shi W; Fang H; Zhang X
Mol Med Rep; 2018 Dec; 18(6):5417-5426. PubMed ID: 30365154
[TBL] [Abstract][Full Text] [Related]
46. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
47. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
48. Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.
Sai B; Xiang J
J Cell Mol Med; 2018 Dec; 22(12):5776-5786. PubMed ID: 30255991
[TBL] [Abstract][Full Text] [Related]
49. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.
Mori A; Masuda K; Ohtsuka H; Shijo M; Ariake K; Fukase K; Sakata N; Mizuma M; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Fujishima F; Unno M
Cancer Sci; 2018 Dec; 109(12):3883-3895. PubMed ID: 30302867
[TBL] [Abstract][Full Text] [Related]
50. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients.
Gruber IV; Hartkopf AD; Hahn M; Taran FA; Staebler A; Wallwiener D; Brucker SY; Hanke J; Fehm T
Anticancer Res; 2016 May; 36(5):2345-51. PubMed ID: 27127142
[TBL] [Abstract][Full Text] [Related]
51. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
52. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
53. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
54. Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.
Luo XL; Deng CC; Su XD; Wang F; Chen Z; Wu XP; Liang SB; Liu JH; Fu LW
Cancer Res; 2018 Jul; 78(13):3532-3543. PubMed ID: 29735544
[TBL] [Abstract][Full Text] [Related]
55. Retrieval of Disseminated Tumor Cells Colonizing the Bone in Murine Breast Cancer Metastasis Models.
Welte T; Yu C; Zhang XH
J Mammary Gland Biol Neoplasia; 2015 Dec; 20(3-4):103-8. PubMed ID: 26490041
[TBL] [Abstract][Full Text] [Related]
56. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
Cackowski FC; Wang Y; Decker JT; Sifuentes C; Weindorf S; Jung Y; Wang Y; Decker AM; Yumoto K; Szerlip N; Buttitta L; Pienta KJ; Morgan TM; Taichman RS
Prostate; 2019 Oct; 79(14):1715-1727. PubMed ID: 31449673
[TBL] [Abstract][Full Text] [Related]
57. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
Hanania EG; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
[TBL] [Abstract][Full Text] [Related]
58. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
Zhao J; Wang Y; Mu C; Xu Y; Sang J
Oncogene; 2017 Aug; 36(35):5023-5034. PubMed ID: 28459460
[TBL] [Abstract][Full Text] [Related]
59. Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau.
Lin H; Zheng L; Li S; Xie B; Cui B; Xia A; Lin Z; Zhou P
Phytother Res; 2018 Apr; 32(4):667-671. PubMed ID: 29368408
[TBL] [Abstract][Full Text] [Related]
60. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
